account_balance
Investment manager · 13F filer · SEC CIK 1615982
Venrock Adviser, LLC
Reported value$3.3Bas of Jun 30, 2026
Positions33 4 new, 4 sold out
Top 10 weight80.4%APGE alone is 34%
FiledAug 1445 days after quarter end
Portfolio · as of Jun 30, 2026
Where the money is
New or addedTrimmedHeld
APGEApogee Therapeutics Inc
34.2%
ORKAOruka Therapeutics Inc
12.0%
ERASErasca Inc
9.9%Added +9%
SYRESpyre Therapeutics Inc
8.0%Trimmed −19%
DNTHDianthus Therapeutics Inc
3.5%
OCULOcular Therapeutix Inc
3.1%
DMRADamora Therapeutics Inc
2.8%
SVRASavara Inc
2.8%Added +7%
JBIO2.2%COGT1.9%VRDN1.8%VOR1.7%APGEApogee Therapeutics Inc
34.2%
ORKAOruka Therapeutics Inc
12.0%
ERASErasca Inc
9.9%Added +9%
SYRESpyre Therapeutics Inc
8.0%Trimmed −19%
DNTH3.5%OCUL3.1%DMRA2.8%SVRA2.8%JBIOCOGTVRDN1.8%VORBoxes show the top 12 stocks, sized against each other. The bar above shows how much of the fund they are. 13F only covers US-listed stocks, so foreign holdings and short positions are missing.
Show the top 12 as a list
APGE Apogee Therapeutics Inc 34.2% HeldORKA Oruka Therapeutics Inc 12.0% HeldERAS Erasca Inc 9.9% Added +9%SYRE Spyre Therapeutics Inc 8.0% Trimmed −19%DNTH Dianthus Therapeutics Inc 3.5% HeldOCUL Ocular Therapeutix Inc 3.1% HeldDMRA Damora Therapeutics Inc 2.8% HeldSVRA Savara Inc 2.8% Added +7%JBIO Jade Biosciences Inc 2.2% HeldCOGT Cogent Biosciences Inc 1.9% Trimmed −18%VRDN Viridian Therapeutics Inc 1.8% Trimmed −16%VOR Vor Biopharma Inc 1.7% Held
What changed